Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | mRNA-4359 |
Synonyms | |
Therapy Description |
mRNA-4359 is an mRNA-based cancer vaccine targeting IDO1 and PD-L1, which potentially increases T-cell response against tumor cells expressing PD-L1 and IDO1 (Ann Oncol (2024) 35 (Suppl_2): S521-S522). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
mRNA-4359 | mRNA 4359|mRNA4359 | mRNA-4359 is an mRNA-based cancer vaccine targeting IDO1 and PD-L1, which potentially increases T-cell response against tumor cells expressing PD-L1 and IDO1 (Ann Oncol (2024) 35 (Suppl_2): S521-S522). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05533697 | Phase Ib/II | mRNA-4359 + Pembrolizumab mRNA-4359 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | AUS | 0 |